Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixazomib - Takeda Oncology

Next Previous
Drug Profile

Ixazomib - Takeda Oncology

Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLARO

Latest Information Update: 14 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals; University of California, San Diego
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Antivirals; Chlorobenzenes; Organic boron compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Amyloid light-chain amyloidosis
  • Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Smoldering multiple myeloma; Waldenstrom's macroglobulinaemia
  • Phase I/II HIV infections
  • No development reported Lupus nephritis; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Bladder cancer; Solid tumours

Most Recent Events

  • 08 Jan 2025 Dana-Farber Cancer Institute, in collaboration with Celgene and Takeda completes a phase II trial in Smoldering multiple myeloma (Combination therapy) in USA (PO) (NCT02916771)
  • 07 Dec 2024 Updated efficacy and adverse events data from the phase II HOVON 143 MM trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 03 Jul 2024 Takeda completes a phase II clinical trials in Amyloidosis in Belgium, Canada, China, Greece, Japan, South Korea, Poland, Singapore, Spain, Sweden, USA (PO) (EudraCT2016-001681-28) (NCT02924272)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top